Having trouble viewing this email? View in your browser.

This is a promotional email intended for healthcare professionals only. VEKLURY® (remdesivir) has a conditional marketing authorisation. A link to the Prescribing Information and Adverse Events reporting can be found at the end of this email.
Since the start of the pandemic, Gilead has been focused on supporting you and your patients. Decades of antiviral expertise and commitment have allowed our timely development of VEKLURY, the first and only antiviral treatment approved for COVID‑19 patients with pneumonia requiring low- or high-flow oxygen or non-invasive ventilation at the start of treatment.*2
In ACTT-1, VEKLURY compared with placebo:
Reduced time to recovery in the overall population (Primary outcome, median 10 days vs 15 days, p<0.001)1
Reduced disease progression to new invasive mechanical ventilation or ECMO in patients who were not receiving either at baseline by 43%
(13% vs 23%, absolute difference -10% [95% CI -15 to -4])1
Mortality rate by Day 29 in the overall population was 11% vs 15% (HR: 0.73 [95% CI 0.52–1.03])†1
In a post-hoc subgroup analysis, VEKLURY reduced mortality in patients on low-flow oxygen at baseline by 70% (HR: 0.30 [95% CI 0.14–0.64])
No difference was observed in other baseline oxygen status subgroups
Demonstrated a generally well-tolerated safety profile vs placebo1
DID YOU MISS IT? Discover the real-world data for remdesivir at ECCMID 2021
New data about remdesivir were presented during the scientific programme at ECCMID 2021 on 12 July 2021. Visit the ‘Interventions for improving COVID outcome’ late-breaker session (S191) on the ECCMID on-demand platform to find out more about the real-world data evaluating the use of remdesivir in hospitalised patients with COVID‑19.
Gilead-sponsored activities at ECCMID 2021
This year at ECCMID, Gilead sponsored several engaging sessions in which world-leading experts shared their insights and perspectives on the multifaceted treatment approach in the management of hospitalised patients with COVID‑19. All sessions are now available ‘on demand’ via the ECCMID platform.
Please login to the ECCMID platform to access this session
Expert opinions on the role of antiviral therapy in the management of hospitalised patients with COVID‑19: Translating data into practice
Originally broadcast on 16 June, Dr David Wohl and Dr Juan Berenguer discuss a holistic approach to treating hospitalised patients with COVID‑19, with a focus on antiviral therapy, and consider how established evidence and emerging data may help to inform future management strategies.
The role of a multifaceted approach in the management of COVID‑19
Join leading experts from across the world as they share their perspectives on the importance of a multifaceted approach and the role of VEKLURY in the management of hospitalised patients with COVID‑19.
Please login to the ECCMID platform to access this session
The role and timing of antiviral therapy in the treatment of COVID‑19
Explore the science behind antiviral therapy and the rationale for targeting SARS-CoV-2 replication directly in this symposium chaired by Prof. Andrew Ustianowski and hosted on 10 July. Listen as our experts provide clarity on how, when and why to use antiviral therapy as part of an overall treatment strategy to improve outcomes in patients with COVID‑19.
* VEKLURY has a conditional marketing authorisation for the treatment of coronavirus disease 2019 (COVID‑19) in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).2
In some other studies, VEKLURY has not demonstrated a statistically significant difference in mortality benefit.3
ACTT, Adaptive COVID-19 Treatment Trial; CI, confidence interval; COVID‑19, coronavirus disease 2019;
ECCMID, European Congress of Clinical Microbiology & Infectious Diseases; ECMO, extracorporeal membrane oxygenation; HR, hazard ratio; RDV, remdesivir; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
1. Beigel JH, et al. N Engl J Med. 2020; 383: 1813–1826.
2. VEKLURY (RDV) 100 mg powder for concentrate for solution for infusion. Summary of Product Characteristics. Gilead Sciences Ltd. Available at: https://www.medicines.org.uk/emc/product/11597/smpc. Accessed July 2021.
3. WHO Solidarity Trial Consortium. N Engl J Med. 2021; 384: 497–511.
This email includes promotional activities which will include materials and discussion of licensed products and are organised and funded by Gilead Sciences Europe Ltd.
Please click here to access VEKLURY (remdesivir) Prescribing Information.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions via the dedicated COVID‑19 Yellow Card reporting site at coronavirus-yellowcard.mhra.gov.uk. Adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500.
This information is intended for healthcare professionals only.
IHQ-VKY-0050 July 2021
This email was received because you have opted in to receiving promotional emails from Gilead.
Privacy Policy

You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe

This newsletter has been sent to: $$EMAIL$$